🔗 Share this article World Health Organization Issues Alert Over Acute Shortage of Weight-Loss Jabs Under one in 10 patients that would benefit from weight-loss injections including Wegovy can access them, caution the WHO as it issues its inaugural recommendations on the medications. With over a billion people worldwide currently obese, it is advocating for more widespread and fairer access to these injectable treatments. According to forecasts, over two billion will be obese by 2030 unless action is taken. "The latest guidelines acknowledges that obesity is a long-term condition that can be managed with thorough and lifelong treatment," stated the agency's head Tedros Adhanom Ghebreyesus. Substantial prices, constrained manufacturing, and distribution challenges are key obstacles to widespread availability to the jabs that can help people shift substantial body mass, notes the body. GLP-1 Therapy Shortage Despite the present most optimistic scenario, the production of these medications might only reach about 100 million people – less than 10% of the global need, per the health organization. The recommendation calls on countries and companies to increase availability, via measures such as licensing agreements. The intellectual property rights on the active ingredient – the core component of Novo Nordisk's Wegovy – is set to lapse in a number of nations in 2026. How Obesity Injections Function These medications mimick a natural hormone to slow digestion, suppress the appetite and boost satiety so users consume fewer calories. Individuals typically begin shedding pounds in the initial weeks of starting on the once-weekly jabs. Evidence suggests people may see weight return within a year of discontinuing the drug, as their usual food cravings come back. Being above a healthy weight increases your risk for experiencing diseases, such as diabetes, cardiovascular issues, brain attack, and specific cancers. Obesity impacts people in every country and was associated with 3.7 million deaths worldwide in 2024, according to the WHO.
Under one in 10 patients that would benefit from weight-loss injections including Wegovy can access them, caution the WHO as it issues its inaugural recommendations on the medications. With over a billion people worldwide currently obese, it is advocating for more widespread and fairer access to these injectable treatments. According to forecasts, over two billion will be obese by 2030 unless action is taken. "The latest guidelines acknowledges that obesity is a long-term condition that can be managed with thorough and lifelong treatment," stated the agency's head Tedros Adhanom Ghebreyesus. Substantial prices, constrained manufacturing, and distribution challenges are key obstacles to widespread availability to the jabs that can help people shift substantial body mass, notes the body. GLP-1 Therapy Shortage Despite the present most optimistic scenario, the production of these medications might only reach about 100 million people – less than 10% of the global need, per the health organization. The recommendation calls on countries and companies to increase availability, via measures such as licensing agreements. The intellectual property rights on the active ingredient – the core component of Novo Nordisk's Wegovy – is set to lapse in a number of nations in 2026. How Obesity Injections Function These medications mimick a natural hormone to slow digestion, suppress the appetite and boost satiety so users consume fewer calories. Individuals typically begin shedding pounds in the initial weeks of starting on the once-weekly jabs. Evidence suggests people may see weight return within a year of discontinuing the drug, as their usual food cravings come back. Being above a healthy weight increases your risk for experiencing diseases, such as diabetes, cardiovascular issues, brain attack, and specific cancers. Obesity impacts people in every country and was associated with 3.7 million deaths worldwide in 2024, according to the WHO.